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background:  In the setting of percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), bivalirudin (B) has been 
shown to be superior to unfractionated heparin (UFH) in reducing major adverse cardiac events, driven by reduction in major bleeding. With 
increasing use of radial access and potent anti-platelet therapy, recent trials suggest that the previous benefit observed with B may now be 
substantially reduced. ACS encompasses both ST-elevation ACS (STE-ACS), with generally high thrombus burden and non-ST-elevation 
ACS (NSTE-ACS), with lower thrombus burden. Whether B offers differential clinical benefit in these 2 groups, is unknown.
methods:  We conducted a meta-analysis of randomized trials comparing B and UFH in patients receiving PCI for ACS divided into STE-
ACS and NSTE-ACS groups. Overall estimates of effect were calculated with a fixed-effects model or random-effects model.
Results:  In STE-ACS, 6 trials (10,368 patients) were identified. Compared to UFH, B increased the risk of myocardial infarction (MI) (OR 
1.41; CI 1.02-1.95; p=0.04) and acute stent thrombosis (ST) (OR 4.44; CI 2.37-8.33; p<0.00001), and reduced the risk of major bleeding 
when comparing B combined with provisional glycoprotein IIb/IIIa inhibitor (GPI) use versus UFH with planned GPI use (OR 0.51; CI 0.41-
0.64; p<0.00001). We identified 15 NSTE-ACS trials (25,250 patients). There was no difference between B and UFH in the occurrence of 
death (OR 0.98; CI 0.71-1.33; p=0.88), MI (OR 1.09; CI 0.98-1.21; p=0.12), or ST (OR 1.20; CI 0.85-1.70; p=0.31). However, B significantly 
reduced the risk of major bleeding compared to UFH, either with provisional use of GPI in both arms (OR 0.62; CI 0.48-0.81; p=0.0005), or 
in B arm only (OR 0.53; CI 0.44-0.63; p<0.00001).
conclusion:  Although in STE-ACS, B is associated with an increased risk of ischemic events, B may confer an advantage over UFH in 
NSTE-ACS patients undergoing PCI, with a reduction in major bleeding and without an increase in ischemic events. Large scale multi-
centre randomized studies are needed to elucidate the optimal anti-thrombotic regimen in patients presenting with STE-ACS undergoing 
PCI in the contemporary era.
